Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Aufman Associates Inc

Aufman Associates Inc lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 26.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 11,066 shares of the company’s stock after purchasing an additional 2,299 shares during the quarter. Aufman Associates Inc’s holdings in Moderna were worth $460,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. State Street Corp raised its stake in Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after purchasing an additional 178,115 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the period. Norges Bank purchased a new stake in Moderna in the fourth quarter valued at approximately $163,833,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after buying an additional 19,819 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Trading Down 3.1 %

NASDAQ:MRNA opened at $31.12 on Friday. The stock has a 50 day moving average of $34.72 and a two-hundred day moving average of $44.62. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The firm has a market cap of $12.03 billion, a P/E ratio of -3.35 and a beta of 1.86.

Analyst Ratings Changes

MRNA has been the subject of several research reports. Berenberg Bank lifted their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Morgan Stanley cut their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Evercore ISI set a $50.00 target price on Moderna in a report on Friday, February 14th. Finally, Bank of America reduced their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.